CM BioHealth has been selected for the Biopharmaceutical Raw Material Commercialization Support Project on domestication on June 19th. CM BioHealth is a company that focuses on innovative research and development in the biohealth field, and through this selection, it is expected to pave the way for an even brighter future. This support project hosted KITA and Inha University, is a program that provides various benefits to accelerate the biopharmaceutical industry and enable domestic companies to be competitive in the global market.  

Included in this are technological development, construction of research infrastructure, and financial support for commercialization. 

Several factors have contributed to CM BioHealth's selection. Exceptional research capabilities and innovative ideas in the development of biopharmaceutical raw materials played a significant role. With these strengths as a foundation, the company's technological prowess is expected to be further enhanced. Additionally, this project is expected to significantly contribute to increasing the competitiveness of the domestic bio-industry.  CM BioHealth's R&D will contribute to the development of biopharmaceutical raw materials with enhanced efficacy and safety through new raw materials. The biopharmaceutical industry is currently emerging as a global trend, and as the market share for biopharmaceuticals increases, the importance of this field is being highlighted more than ever. 

In particular, through this domestication project, it is expected that there will be a significant contribution to South Korea's bio-industry in securing the supply of biopharmaceutical raw materials, which has been more than 90% dependent on foreign countries. Also, experts from various fields are expected to participate in this project, assisting in enhancing CM BioHealth’s R&D capabilities. In conclusion, CM BioHealth’s selection in the Biopharmaceutical Raw Material Commercialization Support Project is expected to bring a significant leap not only to the company but also to South Korea's biopharmaceutical industry. With this, CM BioHealth is expected to take the lead in contributing to the health and prosperity of the nation, fulfilling its social responsibilities and contributions.